Related Experiment Video
Updated: May 12, 2025
Following in Real Time the Impact of Pneumococcal Virulence Factors in an Acute Mouse Pneumonia Model Using Bioluminescent Bacteria
Published on: February 23, 2014
Recurrent invasive pneumococcal disease in children: A retrospective cohort study, England, 2006/07-2017/18
Marta Bertran1, Fariyo Abdullahi1, Joshua C D'Aeth2
1Immunisation and Vaccine Preventable Diseases Division, UK Health Security Agency, 61 Colindale Avenue, London NW9 5EQ, United Kingdom.
Insights
Recurrent invasive pneumococcal disease (IPD) is rare in children, primarily affecting those with comorbidities. Higher-valent pneumococcal conjugate vaccines (PCVs) show promise in reducing recurrent IPD risk.
Area of Science:
- Pediatric Infectious Diseases
- Vaccinology
- Epidemiology
Background:
- Recurrent invasive pneumococcal disease (IPD) is uncommon in pediatric populations.
- Underlying comorbidities are frequently associated with recurrent IPD in children.
- The study period encompassed the introduction of 7-valent (PCV7) and 13-valent (PCV13) pneumococcal conjugate vaccines in England.
Purpose of the Study:
- To assess the incidence and risk factors of recurrent IPD in children.
- To describe the clinical characteristics and outcomes of children experiencing recurrent IPD.
- To evaluate the impact of pneumococcal conjugate vaccines on recurrent IPD rates.
Main Methods:
- Utilized enhanced national surveillance data for laboratory-confirmed IPD cases in children (<15 years) from 2006/07 to 2017/18.
- Assessed recurrence risk, serotypes involved, demographics, comorbidity status, vaccination history, clinical presentation, and outcomes.
- Compared recurrent IPD cases with single-episode IPD cases.
Main Results:
- 2.2% of children surviving their first IPD episode experienced at least one recurrence.
- Recurrence rates were significantly higher in children with comorbidities (10 times) and immunosuppression (30 times).
- All recurrent cases post-PCV13 introduction were caused by non-PCV13 serotypes, suggesting vaccine impact.
Conclusions:
- Recurrent IPD in children is rare and predominantly linked to comorbidities, particularly immunosuppression.
- Higher-valent PCVs hold potential for further decreasing the burden of recurrent IPD in pediatric populations.
- Surveillance data highlights the importance of vaccination and managing comorbidities in preventing recurrent IPD.
Background:
Recurrent invasive pneumococcal disease (IPD) is rare in children and usually associated with underlying comorbidities. We aimed to assess the risk and describe the characteristics of children with recurrent IPD over a 12-year period covering the introduction of the 7-valent (PCV7), followed by the 13-valent (PCV13) pneumococcal conjugate vaccine (PCV) in the national childhood immunisation programme in England.
Methods:
We used enhanced national surveillance data for England and included all laboratory-confirmed IPD cases in children (<15 years) during 2006/07-2017/18. We assessed the risk and rate of recurrent IPD, the serotypes responsible and the demographics, comorbidity status and prevalence, vaccination status, clinical presentation and outcomes in children with recurrent IPD compared to those with a single IPD episode.
Findings:
There were 5158 IPD episodes reported in 5033 children over 12 years and 2.2% (105/4814) of those surviving their first IPD had at least one recurrence. Recurrence risk decreased with increasing age and over time. During 2015/16-2017/18, five years after PCV13 replaced PCV7, IPD recurrence rate was 229.0 (95% CI 154.8-339.0) per 100,000 person-years, with all recurrent cases caused by non-PCV13 serotypes. Where serotype information was available, recurrence was due to the same serotype in 25 cases, with a shorter median (IQR) interval of 88 (57-177) days between recurrent episodes, and in 60 cases due to different serotypes, with a median (IQR) interval of 223 (125-574) days (p=0.001). Compared to healthy children (103.0; 95%CI 63.1-168.1), recurrence rate per 100,000 person-years was 10 times higher in children with any comorbidity (1061.0; 95% CI 827.2-1360.9; 62/78 [79.5%] with available information had comorbidities), and almost 30 times higher in immunosuppressed children (2788.5; 95%CI 2029.0-3832.2; 38/78 [48.7%] were immunosuppressed). The 30-day case-fatality rate after recurrent IPD was 2.9% (3/105) compared to 4.4% (219/4928; p=0.63) after single-episode IPD.
Interpretation:
Recurrent IPD is rare in children and occurs mainly in children with comorbidities, especially immunosuppression. Higher-valent PCVs have the potential to further reduce the risk of recurrent IPD in children.
More Related Videos
06:06Constructing Mutants in Serotype 1 Streptococcus pneumoniae strain 519/43
Published on: September 11, 2020
12:21A Mouse Model for the Transition of Streptococcus pneumoniae from Colonizer to Pathogen upon Viral Co-Infection Recapitulates Age-Exacerbated Illness
Published on: September 28, 2022
Related Concept Videos
01:30Pneumonia I: Introduction
Risk Factors
Various factors influence the likelihood of developing pneumonia. Age plays a crucial role, with infants, children under two, and individuals over 65 at increased risk due to their...
01:30Pneumonia III: Complications and Assessment
01:27Pneumothorax-II
Clinical Manifestations:
01:28Pneumonia IV: Management
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include: